Tuesday

BioTech Webinars

Oct. 26th

1

11AM – 12PM ET

Will clinical progress in therapies that promise a genetics-based cure for devastating rare diseases lead to similar downstream progress in patient access to these high-cost, high-touch treatments?

Category: Rare Genetic Disorders

Chair:
Michael Ringel, JD PhD
Managing Director and Senior Partner

BCG

 

WHO IS SPEAKING


Scott T. Rottinghaus, M.D.
VP, Head of Clinical Development, Hematology & Nephrology
Alexion Pharmaceuticals

 

> More about the product

Ultomiris_logo
Pushkal_Garg_Alnylam_BioTech_Web_3

Pushkal Garg, M.D.
Chief Medical Officer
Alnylam

 

> More about the product (GIVLAARI)

> More about the product (OXLUMO)

Jeffrey P. Castelli, Ph.D.
Chief Development Officer
Amicus Therapeutics

 

> More about the product

Shephard Mpofu, M.D.
Senior Vice President and Chief Medical Officer
Novartis

 

> More about the product

Kim Smith-Whitley, M.D.
Executive Vice President and Head of Research and Development
GBT

 

> More about the product

David Jacoby M.D., Ph.D.
Fellow for Clinical Sciences and Vice President Discovery Medicine
BioMarin

 

> More about the product

Ashley Yegin, MD, MBA 
Global Medical Unit Head, Rare Disease/HAE
Takeda

 

> More about the product


2

12PM – 1PM ET

Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other rare conditions, particularly blood-based hematologic disorders?

Category: Cancer and other Rare Diseases

Chair:
Alisa Wilson, PhD
Managing Director, Life Sciences
Accenture

WHO IS SPEAKING


Javad Shahidi, MD, MSc
Vice President, Global Oncology R&D
Daiichi Sankyo

 

> More about the product

Ira Gupta
MD Vice President, Medicines Development Leader – Global Oncology Therapy Area
GSK

Rui de Passos Sousa, MD, MSc
Global Medical Head for the TTP program
Sanofi

 

> More about the product

Elizabeth H.Z. Thompson, PhD, EVP
Research and Development
Horizon

 

> More about the product


3

1PM – 2PM ET

Given that many chronic diseases have an infectious origin, what learnings can be had by the most recent innovations in vaccine development technology in raising the bar on innovations to address the huge unmet need against chronic conditions that kill millions?

Category: Vaccines, Infectious and Chronic Diseases

Michael_Rosenblatt

Chair:
Dr. Michael Rosenblatt, MD
Senior Partner

Flagship Pioneering

WHO IS SPEAKING


Sally Stephens
Corporate Strategy, Business Development, Marketing/Sales, and the Developing Countries Program
Medicines360

Bola Akinlade, MD
Vice President, Clinical Sciences, Immunology and Inflammation
Regeneron

 

> More about the product